Geneoscopy settles Delaware litigation with Abbott's Exact Sciences
All claims and counterclaims have been dismissed; Geneoscopy says the remaining settlement terms are confidential.

The pending Delaware litigation over ColoSense has ended as privately held Geneoscopy, Inc. announced a settlement on Tuesday with Exact Sciences Corporation, a subsidiary of Abbott Laboratories NYSEABT. Two patent-board rulings had found all 30 challenged claims unpatentable, according to Geneoscopy.
In its Nov. 17 announcement, Geneoscopy said the U.S. District Court for the District of Delaware dismissed all claims and counterclaims. Exact Sciences' patent claims against commercial ColoSense and its false or misleading advertising claims were dismissed with prejudice. Other settlement terms are confidential.
Geneoscopy is a St. Louis diagnostics developer focused on stool-based RNA tests for gastrointestinal disease.
Abbott completed its acquisition of Exact Sciences on March 23, and Exact Sciences' final Nasdaq trading day was March 20. Abbott shares closed at US$107.45 in New York on Nov. 16 at 4:02 p.m. EST, according to Google Finance NYSEABT. That close predates the settlement announcement.
Geneoscopy's release is the source for the dismissal account; the court order and settlement agreement were not independently reviewed. The announcement discloses neither a payment amount nor a licensing arrangement, so it supplies no basis for quantifying a settlement gain or cost for Abbott.
"The settlement is not an admission of liability or wrongdoing by either party," Geneoscopy said in its Nov. 17 release.
ColoSense Was Already Available Nationwide
The settlement follows commercial access already established through Labcorp Holdings Inc. NYSELH. Labcorp announced nationwide availability on June 22, describing a commercial collaboration with Geneoscopy and coverage for eligible Medicare and Medicare Advantage beneficiaries.
That sequence places the legal resolution after the nationwide launch, rather than establishing a new sales-start date. Labcorp's June release also described additional commercial insurance coverage as available, without putting a number on covered commercial lives.
ColoSense detects colorectal-neoplasia-associated RNA markers and occult haemoglobin in stool, according to Geneoscopy's Nov. 17 release. The company describes its FDA-approved test as a screening option for average-risk adults aged 45 and older.
Geneoscopy recommends further diagnostic assessment after a positive result and says the healthcare provider should determine the appropriate follow-up, including colonoscopy. Geneoscopy says ColoSense does not replace diagnostic or surveillance colonoscopy for high-risk individuals.
Read more: GRAIL gets 7-2 FDA panel backing for Galleri cancer test
Abbott's March acquisition release identifies Cologuard as its noninvasive colorectal cancer screening offering. Its broader acquired portfolio also includes tests for treatment selection, recurrence monitoring and multi-cancer early detection, placing this dispute within a larger cancer-diagnostics business.
Read more: Guardant Health adds five epigenomic tools for cancer treatment selection
Labcorp shares closed at US$372.46 in New York on Nov. 16 at 4:00 p.m. EST, according to Google Finance NYSELH. That dated sector comparison also precedes Geneoscopy's announcement and establishes no settlement-related reaction.
Patent Decisions Preceded Settlement
Geneoscopy said the first patent-board ruling, in July 2025, found all 20 challenged claims of the '781 patent unpatentable as obvious. In February 2026, the board reached the same conclusion on all 10 challenged claims of the '746 patent.
The company says those decisions covered every patent claim Exact Sciences asserted against it in litigation. It also says Exact Sciences withdrew its preliminary-injunction motion in August 2025, after seeking to keep ColoSense off the market.
The Nov. 17 announcement sets no next court date or commercial deadline. The confidential agreement leaves any payment, licensing or other market-access terms outside the public account.
Adrian Kessler






